Eyepoint Pharmaceuticals advances new therapies for serious retinal diseases in June campaign

Eyepoint Pharmaceuticals advances new therapies for serious retinal diseases in June campaign
Eyepoint eyes new retinal therapies

Eyepoint Pharmaceuticals is advancing potential therapies targeting serious retinal diseases such as diabetic macular edema (DME) as part of its observance of Mens Health Month in June.

The company emphasizes its commitment to improving patient outcomes through ongoing research and development in ophthalmology. Eyepoint Pharmaceuticals encourages patients and healthcare professionals to learn more about its latest efforts to address significant unmet medical needs in retinal care.

Eyepoint operates a research facility in Northbridge focused on developing new therapies for retinal disease patients, according to a previous company update. The company’s Chief Executive, Jay S. Duker, has also discussed advances in OCT retina imaging tools that have impacted retina care in recent years, as reported in a separate interview. These activities reflect Eyepoint’s ongoing involvement in ophthalmology innovation.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.